What Is Immune Microenvironment Engineering?
7 月 23, 2026Core Framework & DiagramWhat Is Immune Microenvironment Engineering?
7 月 23, 2026
What Is Immune Microenvironment Engineering?
An impenetrable fortress can't be overcome only by stronger soldiers — the fortress itself needs to be transformed
As covered in Article 69, the tumor microenvironment (TME) is the 'moat' tumors build — hypoxia, high lactate, immunosuppressive signals, physical barriers — making immune cells unable to work effectively even when they reach the tumor.
Immune checkpoint inhibitors removed the PD-1/PD-L1 blockade, but the moat has many other obstacles.
Immune Microenvironment Engineering is a more radical direction: not just removing one blockade, but systematically transforming the entire tumor microenvironment — changing it from an 'immune forbidden zone' to a place conducive to immune cell activity and combat.
This direction represents tumor immunotherapy's next-generation paradigm upgrade from 'activating immunity' to 'transforming the battlefield.'
核心要点
01
Immune microenvironment engineering's paradigm upgrade: from 'giving better immune cells' to 'transforming the battlefield that makes immune cells unable to work' — necessary next step for overcoming solid tumor obstacles in tumor immunotherapy.
02
Vessel normalization (moderate anti-VEGF) is key to opening 'entry channels': improving oxygen supply + enhancing immune cell extravasation efficiency, already approved in liver cancer as combination regimen (atezolizumab + bevacizumab 2020).
03
STING agonists (intratumoral injection) are the most direct innate immune activation tool for 'warming cold tumors,' combined with PD-1 inhibitors in advancing clinical trials.
04
CAF targeting (elimination/reprogramming/matrix softening) is the core strategy for breaking solid tumor physical barriers; pancreatic cancer is the most urgent application scenario.
05
Oncolytic viruses (T-VEC, FDA approved 2015) lyse tumors internally, trigger inflammation, activate immunity — the most comprehensive 'cold tumor warming' strategy. OV + checkpoint inhibitors is currently the most-watched combination in clinical trials.
06
Local delivery technology (intratumoral injection, hydrogel sustained-release, nanoparticle targeting) precisely delivers microenvironment transformation tools, reducing toxicity while increasing efficacy — one of next-generation tumor immunotherapy's most promising technical routes.
Art 136
What Is Immune Nanotechnology?
→
Art 137
What Is Immune AI?
→
